Weiling Medical Raises Over RMB 100M for Fully Implantable BCI Systems
Summary
Weiling Medical, founded in 2019, closed a financing round of more than RMB 100 million led by Junzhong Capital, with Shanghai STAR Market-listed Innotek serving as the fund's core industrial investor. The company develops fully implantable BCI systems aimed at treating severe brain injuries and neurological disorders, with hardware spanning electronic implants, external controllers, neurostimulators, and exoskeleton-style assistive devices. Proceeds will fund clinical validation of its core implantable products, medical-device registration filings, manufacturing scale-up, and expanded clinical applications in neurological function repair.
Why it matters
Industrial-investor participation, rather than purely financial VC backing, signals growing confidence that implantable BCI hardware in China is nearing real clinical and manufacturing scale.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial